Iovance Biotherapeutics (IOVA) Expected to Announce Earnings on Tuesday

Iovance Biotherapeutics (NASDAQ:IOVA) is anticipated to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $81.6050 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Iovance Biotherapeutics Stock Performance

Shares of IOVA opened at $2.87 on Monday. Iovance Biotherapeutics has a twelve month low of $1.64 and a twelve month high of $6.09. The firm’s 50 day moving average price is $2.59 and its two-hundred day moving average price is $2.39. The firm has a market cap of $1.14 billion, a P/E ratio of -2.39 and a beta of 0.76.

Analysts Set New Price Targets

IOVA has been the topic of several research reports. Barclays boosted their price objective on shares of Iovance Biotherapeutics from $9.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Chardan Capital cut their price target on Iovance Biotherapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Thursday, November 6th. HC Wainwright reduced their price objective on Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, October 29th. Finally, The Goldman Sachs Group reissued a “sell” rating and issued a $2.00 target price on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $10.50.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in IOVA. Xponance LLC boosted its holdings in shares of Iovance Biotherapeutics by 19.4% in the 4th quarter. Xponance LLC now owns 24,288 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 3,950 shares during the last quarter. Raymond James Financial Inc. raised its position in Iovance Biotherapeutics by 1.4% during the second quarter. Raymond James Financial Inc. now owns 324,098 shares of the biotechnology company’s stock worth $557,000 after acquiring an additional 4,618 shares in the last quarter. Captrust Financial Advisors lifted its stake in Iovance Biotherapeutics by 13.5% in the fourth quarter. Captrust Financial Advisors now owns 46,812 shares of the biotechnology company’s stock valued at $128,000 after acquiring an additional 5,563 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Iovance Biotherapeutics by 2.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 231,443 shares of the biotechnology company’s stock valued at $637,000 after acquiring an additional 6,228 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its position in shares of Iovance Biotherapeutics by 20.4% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 40,958 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 6,933 shares during the period. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.